Significados de myeloablative conditioning en inglés

Fifty-eight patients received a sequential approach and 41 patients a myeloablative conditioning regimen.

However, morbidity associated with myeloablative conditioning and graft-versus-host disease has limited its utility.

SCT have previously been limited to full intensity myeloablative conditioning regimens.

The patients receiving reduced intensity conditioning were elderly, or exhibited contraindications for myeloablative conditioning.

FluTreo has myeloablative properties but lower toxicity and replaced standard myeloablative conditioning at our center in 2014.

Multivariate analysis identified age, disease status and the use of myeloablative conditioning as independent prognostic factors for OS.

Forty-eight percent received a myeloablative conditioning regimen and 78% received stem cells from matched sibling donors.

In contrast to conventional chemoradiotherapy secondary malignancies of the host's haemopoiesis are rare due to the myeloablative conditioning.

For a CMV-seropositive patient, our data support selecting a CMV-seropositive donor if the patient receives a myeloablative conditioning regimen.

The patients underwent transplantation following myeloablative conditioning; the recipients and donors were matched through the Japan Marrow Donor Program.

Most recipients of allogeneic hematopoietic stem cell transplantation suffer from secondary infertility owing to gonadal damage from myeloablative conditioning.

Our data indicate that HSCT following myeloablative conditioning is curative and associated with acceptable risks as a treatment option for XLT.

Further, chronic graft-versus-host disease had a dramatic impact on thymic function, as observed previously in patients given grafts after myeloablative conditioning.

In all, 56 patients received myeloablative conditioning regimens and 12 received a reduced-intensity, fludarabine-based conditioning regimen.

Enthusiasm for ASCT in PMF has been muted due to an unacceptable transplantation-related morbidity and mortality in patients receiving fully myeloablative conditioning regimens.

The ability to stably genetically modify HSPCs without the need of myeloablative conditioning is relevant for a broader clinical application of gene therapy.